Recruiting

64Cu-NODAGA-CANF

Sponsor:

Washington University School of Medicine

Code:

NCT07916883

Conditions

Carotid Atherosclerosis

Carotid Artery Stenosis Asymptomatic

Asymptomatic Carotid Artery Stenosis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

64Cu-NODAGA-CANF

Optimal Medical Therapy (OMT)

Carotid Endarterectomy (CEA) surgery

Study Details

Brief summary:

The goal of this clinical trial is to evaluate the feasibility of imaging atherosclerosis by 64Cu-NODAGA-CANF PET-MR in a pilot study of patients with asymptomatic carotid artery stenosis (ACAS). The main question it aims to answer is:

Can 64Cu-NODAGA-CANF PET detect carotid atherosclerosis in patients with ACAS?

Uptake of 64Cu-NODAGA-CANF as measured by PET-MR will also be correlated to anatomic features of plaque on MRI, outcomes for patients treated with optimal medical therapy (OMT) alone or OMT and carotid endarterectomy (CEA) surgery, and tissue measurements for patients undergoing CEA surgery. The ability of 64Cu-NODAGA-CANF to risk stratify ACAS patients treated with OMT alone with respect to patient outcomes will be determined.

Participants will

  • Receive a single intravenous (IV) administration of 64Cu-NODAGA-CANF followed by dynamic PET-MR imaging for up to 60 minutes and a second optional scan between 1-4 hours post-injection.
  • Undergo physical examinations, vital sign measurements, and blood and urine collection for clinical laboratory tests.
  • Undergo standard of care treatment with either OMT alone or OMT and CEA surgery.
  • Be evaluated with phone interviews 48-72 hours (2-3 days) after discharge and every 3 months (+/- 5 days) to assess for ipsilateral ischemic cerebrovascular event (transient ischemic attack (TIA), stroke) or remote ipsilateral carotid intervention.

Conditions

Carotid Atherosclerosis

Carotid Artery Stenosis Asymptomatic

Asymptomatic Carotid Artery Stenosis

Study ID

NCT07916883

Start date

Nov 18, 2026

Status verified date

Nov, 2026

Completion date

May 31, 2027

Anticipated

Primary completion date

May 31, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Adults, 18 years of age or older.
  • Asymptomatic carotid artery stenosis patients who have undergone carotid Doppler/ultrasound imaging or other carotid imaging which have demonstrated a ≥ 60% diameter carotid artery stenosis.
  • The treating surgeon has planned either treatment with optimal medical therapy (OMT) alone or OMT and carotid endarterectomy (CEA) surgical intervention.

Exclusion Criteria:

  • Inability to receive and sign informed consent.
  • Patients with an unstable clinical condition that in the opinion of the Sponsor-Investigator or designee precludes participation in the study.
  • Inability to tolerate up to 60 minutes in a supine position with arms down at sides for PET-MR imaging.
  • Prior history of carotid endarterectomy (CEA) or carotid artery stent procedure on the ipsilateral side.
  • Past medical history of transient ischemic attack (TIA) or stroke within the last 6 months.
  • Unwilling to comply with study procedures and/or unable to be available for the duration of the study outlined in the protocol.
  • Claustrophobia or other preventing condition that has previously or would interfere with completion of imaging as outlined in the protocol.
  • Participation in another research study with an investigational drug, including a diagnostic or therapeutic radiopharmaceutical, currently or within the last year.
  • Contraindications to MR imaging (pacemaker, brain aneurysm clips, shrapnel, claustrophobia, etc.).
  • Currently pregnant or lactating. All female subjects of childbearing potential must have a documented negative pregnancy test (serum or urine hCG) performed within 24 hours immediately prior to the administration of 64Cu-NODAGA-CANF or documented post-menopausal defined as the cessation of menses for ≥ 12 months or documentation of having a bilateral oophorectomy and/or hysterectomy.

Study Design

Enrollment

30 participants

Anticipated

Interventions and Outcome Measures

Arms

Patients treated with Optimal Medical Therapy (OMT) alone

Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler or other carotid imaging with ≥ 60% diameter stenosis who are clinically referred for OMT alone.

Patients treated with OMT and carotid endartarectomy (CEA)

Asymptomatic carotid artery stenosis (ACAS) patients with known carotid artery atherosclerosis by ultrasound/Doppler or other carotid imaging with ≥ 60% diameter stenosis who are clinically referred for OMT and CEA.

Interventions

64Cu-NODAGA-CANF

Patients will receive a single intravenous (IV) injection of 8-10 mCi of 64Cu-NODAGA-CANF for PET-MR imaging at the imaging visit.

Optimal Medical Therapy (OMT)

Patients will receive optimal medical therapy (OMT) as part of their standard of care treatment.

Carotid Endarterectomy (CEA) surgery

Patients will undergo carotid endarterectomy (CEA) surgery as part of their standard of care treatment. The plaque specimen will be collected during surgery for ex vivo tissue measurements.

Primary outcome measure

  • Comparison of 64Cu-NODAGA-CANF PET SUV (Standardized Uptake Value) between the atherosclerosis of the target diseased carotid artery and the non-diseased contralateral carotid artery or non-diseased vertebral artery [ Time Frame: Up to 4 hours post-injection of 64Cu-NODAGA-CANF ]

Central Contacts and Locations

Central contacts

Locations

Washington University School of Medicine

Recruiting

St Louis, Missouri, United States, 63110

Contacts

Pamela K. Woodard, MD

314-362-7100woodardp@wustl.edu

Principal Investigator:

Pamela K. Woodard, MD

More Information

Sponsor

Washington University School of Medicine

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Keywords

  • radiotracer
  • Positron Emission Tomography (PET)
  • Atherosclerosis
  • Cardiovascular Diseases
  • Carotid Artery Diseases
  • Stroke
  • Transient Ischemic Attack (TIA)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Washington University School of Medicine on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.